The FDA approves AstraZeneca’s (NYSE:AZN)
blood thinner Brilinta (ticagrelor), combined with aspirin, for
reducing the risk of a first heart attack or stroke in high-risk
patients with coronary artery disease.
The med was first approved in the U.S. in July 2011 for acute coronary syndrome.
https://seekingalpha.com/news/3578904-fda-oks-expanded-use-of-astrazenecas-brilinta
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.